HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chello, M. Articles by Spampinato, N. Search for Related Content PubMed PubMed Citation Articles by Chello, M. Articles by Spampinato, N.

The Annals of Thoracic Surgery, Vol 58, 1427-1432, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting

M Chello, P Mastroroberto, R Romano, E Bevacqua, D Pantaleo, R Ascione, AR Marchese and N Spampinato
Department of Cardiac Surgery, Medical School of Catanzaro, Italy.

To evaluate the effect of coenzyme Q10 in reducing postoperative cardiac complications after ischemia and reperfusion, we randomly divided 40 patients undergoing elective coronary artery bypass into two groups: patients in group 1 received coenzyme Q10 (150 mg/day) for 7 days before operation, and those in group 2 were the control group. Concentrations of thiobarbituric acid-reactive substances (malondialdehyde), conjugated dienes, and cardiac isoenzymes of creatine kinase were measured in samples from both arterial and coronary sinus sites. Serial sampling was performed 5 minutes after heparin administration, at 10 and 30 minutes during cardiopulmonary bypass, 15 and 30 minutes after aortic cross-clamp removal, and 5 minutes after protamine administration. The concentrations of malondialdehyde, conjugated dienes, and creatine kinase in group 1 were significantly lower than those in group 2. The decrease in plasma malondialdehyde concentrations correlated positively with the decrease in creatine kinase levels in the coronary sinus. The treatment group showed a significantly lower incidence of ventricular arrhythmias during the recovery period than did the control group (p < 0.05). Although the percentage of patients requiring inotropic agents was not significantly different between the two groups, the mean dosage of dopamine required to maintain stable hemodynamics was significantly lower in patients of group 1 than in those of group 2 (p < 0.01). Our findings suggest that pretreatment with coenzyme Q10 may play a protective role during routine bypass grafting by attenuating the degree of peroxidative damage.

This article has been cited by other articles:

				F. Rosenfeldt, S. Marasco, W. Lyon, M. Wowk, F. Sheeran, M. Bailey, D. Esmore, B. Davis, A. Pick, M. Rabinov, et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 25 - 32. [Abstract] [Full Text] [PDF]

				A. E. Vento, J. Aittomaki, K. A. Verkkala, L. J. Heikkila, J. A. Salo, J. Sipponen, and O. J. Ramo Nitecapone as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting Ann. Thorac. Surg., August 1, 1999; 68(2): 413 - 420. [Abstract] [Full Text] [PDF]

				P. K Singal, N. Khaper, V. Palace, and D. Kumar On the role of coenzyme Q10 in cardiovascular diseases Cardiovasc Res, July 1, 1999; 43(1): 250 - 251. [Full Text] [PDF]

				D. P. Taggart, M. Jenkins, J. Hooper, L. Hadjinikolas, M. Kemp, D. Hue, and G. Bennett Effects of Short-Term Supplementation With Coenzyme Q10 on Myocardial Protection During Cardiac Operations Ann. Thorac. Surg., March 1, 1996; 61(3): 829 - 833. [Abstract] [Full Text]